Optimizing Characterization of NSCLC Through Specialty Collaboration

Slides:

Advertisements

Similar presentations

A 74 year old man underwent open prostatectomy due to moderate to severe urinary symptoms unresponsive to medical therapy. Preoperative PSA was 4.1 Postoperatively.

Advertisements

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

Big Data in Genomics, Diagnostics, and Precision Medicine

Where Are We on the Path to Elimination of Chronic Hepatitis C?

Plasma Droplet Digital PCR for Detection of EGFR and KRAS Mutations in Patients With Advanced Nonsquamous NSCLC Slideset on: Sacher AG, Paweletz C, Dahlberg.

Fig 1A. Patient enrollment flow chart

Patient Case 1 Patient Case 1: PET/CT Scan.

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Challenges in RAS Wild-Type mCRC

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Yes, Patient #1 Yes, Patient #3 EGFR sequencing chromatograms

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

Regulatory Industry Statistics Workshop 2018

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Optimizing Outcomes in the Management of GIST

Monitoring EGFR mutation status in Non-small cell lung cancer (NSCLC) patients using circulating Tumour DNA (ctDNA). Matthew Smith Molecular Pathology.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Counseling Patients About Germline BRCA Mutations

Follow-Up of the Patient After PE

Liquid Biopsy for RAS Screening in CRC: How Can We Successfully Implement This New Paradigm?

A, baseline and 4-week PET scan from patient 2 (MET c

More Than Meets the Eye.

Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Progress of the NSCLC Revolution

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

Representative CT and PET/CT images of three patients with NSCLCs

A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Perspective on the Multidisciplinary Management of PAH

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Successful Treatment with Gefitinib in Advanced Non–Small Cell Lung Cancer after Acquired Resistance to Osimertinib Nuria Chic, MD Journal of Thoracic.

AMD Therapy: Where Are We Now and Where Are We Going?

Checkpoint Inhibitors in First-Line Advanced NSCLC

Optimizing Outcomes in Patients With NSCLC and Liver Metastases

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Next-Generation Sequencing and ctDNA

Combining Immunotherapy and Chemotherapy in NSCLC

Representative CT and PET/CT images of three patients with NSCLCs

Opening remarks Welcome to CUP 2019: Cancer of Unknown Primary in the Era of Precision Medicine Focus: Contemporary Clinical Management and International.

Molecular heterogeneity drives secondary resistance to anti-EGFR therapies in mCRC. Molecular heterogeneity drives secondary resistance to anti-EGFR therapies.

Updates in Best Practices in Non-Small Cell Lung Cancer

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Optimizing Characterization of NSCLC Through Specialty Collaboration

Introduction/Background

Individualized Therapy for NSCLC

Considerations for Tissue Collection

CT-Guided Biopsy in a Supine Patient

Complication Rates for PNB of the Lung

Types of Biopsies and Techniques

Coaxial Biopsy Technique

Other Types of Lung Biopsy

Molecular Testing at Diagnosis

Reflex Testing

Molecular Testing Results and Treatment Selection

Osimertinib as 1L Therapy

Molecular-Only Protocol

Molecular Testing Tips and Tricks: Top Priorities

Biopsying Effusions and Ascites

Acquired Resistance

Patient Case: 75-Year-Old Female With Advanced NSCLC EGFR Exon 19del Mutation

Patient Case (cont): PNB Requested on Growing Liver Metastasis

Important Tips to Avoid Delays and Mistakes

Institutional Differences in Tissue Collection

Liquid Biopsy

Abbreviations

Abbreviations (cont)